Ann: Telix Completes Acquisition of IsoTherapeutics, page-3

ITG

"the company scientists, while employed at the DOW chemical company, developed QUADRAMET .... treatment of bone pain due to metastatic cancer treatments ..... "

ive noticed this theme popping up and being discussed more recently.
must be an area TLX are looking to expand more into ?

and
QSAM

About the Technology•“Next generation” bone seekingtargeted radiopharmaceuticals•Based on a proven isotope platformfor this application: 153Sm (samarium)•Two major potential applications–Palliative / pain management ofosteoblastic bone metastases (low dose)–Osteosarcoma therapy, including potential application in paediatric osteosarcoma

....Potential for rapid pathway to commercialisation

from AGM ..

Dr Behrenbruch will speak to you today about the three components of our M&A strategy, whichenable us to now scale-up a complete radiopharmaceutical ecosystem – that takes us from researchand development, through isotope production to the delivery of innovative theranostic solutions forpatients, across the continuum of diagnosis, surgery and therapy, including end-of-life care. Thesecommercial goals and objectives are highly aligned with our stated Company purpose and values ofhelping people with cancer and rare diseases live longer, better quality lives.


and now the 15% is refreshed !!!


"A vote in favour of the resolutions today will refresh our 15% placement capacity, providing theCompany with optionality to pursue further growth opportunities over the next 12 months"